2024-02-23 07:54:24 ET
DENVER, Colo., Feb 23, 2024 (www.247marketnews.com)- Clearmind Medicine Inc. (NASDAQ: CMND ) stated, this morning, that it received approval from the Ministry of Health of Israel to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company’s proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsule.
Clearmind is trading at $2.00, up $0.14 (+7.53%), on trading volume of 1,420,383 shares.
Its 52-week range is $0.9205 to $151.254 and this morning’s premarket high is $2.47.
“We are thrilled to receive approval to commence our phase I/IIa clinical trial for our lead drug candidate, CMND-100, which has been shown to be safe and effective in preclinical studies. This is the most important milestone for the company to date and marks our transition to a clinical- stage pharmaceutical company. The Clearmind team has been working tirelessly on the research and development of a novel treatment to the global epidemic of alcoholism. We are eager to continue our work with patients in need of help,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. “Our non-hallucinogenic, psychedelic solution could be the answer to the tremendous global need for groundbreaking, dedicated and effective treatments for addictions.”
The post Clearmind Medicine Receives MHI Green Light for its Phase I/IIa Clinical Trial first appeared on 24/7 MarketNews .
For further details see:
Clearmind Medicine Receives MHI Green Light for its Phase I/IIa Clinical Trial